The Global Circulating Tumor Cells (CTC) Market Will Grow to USD 18.41 Billion by 2026, at a CAGR of 14.1% – GlobeNewswire

Dublin, April 05, 2022 (GLOBE NEWSWIRE) -- The "Global Circulating Tumor Cells (CTC) Market (2021-2026) by Technology, Application, Product, Specimen, End-User, and Geography, Competitive Analysis and the Impact of Covid-19 with Ansoff Analysis" report has been added to ResearchAndMarkets.com's offering.

The Global Circulating Tumor Cells (CTC) Market is estimated to be USD 9.52 Bn in 2021 and is expected to reach USD 18.41 Bn by 2026, growing at a CAGR of 14.1%.

Key factors such as the growing incidence of cancer followed by the increasing potential of CTCs in diagnosis and treatment have been a prominent driver for the Global Circulating Tumor Cells (CTC) Market.

Similarly, the shifting preference towards minimally invasive diagnostic methods and higher awareness about cancer has led to preventive initiatives taken by individuals in demand for preventive medicines.

However, factors such as lack of awareness and technical difficulties in detection are likely to restrain the market growth. Moreover, stringent government regulations and reluctance to adopt novel CTC technologies are posing to cause significant challenges for the market growth.

Market Segmentation

Company Profiles

Some of the companies covered in this report are Aviva Biosciences, Advanced Cell Diagnostics, Biocept, LungLife AI, Creatv Micro Tech, Miltenyi Biotec, Menarini Silicon Biosystems, Precision for Medicine, Qiagen, etc.

Key Topics Covered:

1 Report Description

2 Research Methodology

3 Executive Summary3.1 Introduction3.2 Market Size and Segmentation3.3 Market Outlook

4 Market Influencers4.1 Drivers4.1.1 Growing Incidence of Cancer and Potential Of CTC In Diagnosis and Treatment4.1.2 Increasing Demand for Preventive Medicine and Companion Diagnostics4.1.3 Increasing Preference for Non-Invasive Methods Cancer Diagnosis4.2 Restraints4.2.1 Stringent Government Regulations4.2.2 Technical Difficulties in Detection4.2.3 High Variability Among Patient Samples and Assays in Immuno-Oncology Trials4.3 Opportunities4.3.1 Increasing R&D Activities in CTC Analysis and Detection Practices4.3.2 Advancements in Chip Technology4.3.3 Emergence of New Single-Cell Technologies4.4 Challenges4.4.1 Lack Of Awareness4.4.2 Reluctance For the Adoption of Novel CTC Technologies

5 Market Analysis5.1 Regulatory Scenario5.2 Porter's Five Forces Analysis5.3 Impact of COVID-195.4 Ansoff Matrix Analysis

6 Global Circulating Tumor Cells (CTC) Market, By Technology6.1 Introduction6.2 CTC Enrichment6.2.1 Immunocapture/Label-Based6.2.1.1 Positive Selection6.2.1.2 Negative Selection6.2.2 Size-Based Separation/Label-Free6.2.2.1 Membrane-Based Size Separation (Label-Free)6.2.2.2 Microfluidic-Based Size Separation (Label-Free)6.2.3 Density-Based Separation (Label-Free)6.2.4 Combined Methods (Label-Free)6.3 CTC Direct Detection6.3.1 Microscopy6.3.2 SERS6.3.3 Immunocytochemical Technology6.3.4 Molecular (RNA)-Based Technology6.3.5 Others6.4 CTC Analysis & Downstream Assays

7 Global Circulating Tumor Cells (CTC) Market, By Application7.1 Introduction7.2 Multiple Chromosome Abnormalities7.3 RNA Profiling7.4 Protein Expression7.5 Cellular Communication

8 Global Circulating Tumor Cells (CTC) Market, By Product8.1 Introduction8.2 Devices or Systems8.3 Kits & Reagents8.4 Blood Collection Tubes

9 Global Circulating Tumor Cells (CTC) Market, By Specimen9.1 Introduction9.2 Blood9.3 Bone Marrow9.4 Other Body Fluids

10 Global Circulating Tumor Cells (CTC) Market, By End User10.1 Introduction10.2 Research & Academic Institutes10.3 Hospitals/ Clinics10.4 Diagnostic Centers

11 Global Circulating Tumor Cells (CTC) Market, By Geography11.1 Introduction

12 Competitive Landscape12.1 Competitive Quadrant12.2 Market Share Analysis12.3 Strategic Initiatives

13 Company Profiles

For more information about this report visit https://www.researchandmarkets.com/r/9nffnt

Read more here:
The Global Circulating Tumor Cells (CTC) Market Will Grow to USD 18.41 Billion by 2026, at a CAGR of 14.1% - GlobeNewswire